Optimized pyroelectric properties of 0-3 composites of PZT particles in polyurethane doped with lithium perchlorate.

A substantial improvement in the performance of pyroelectric 0-3 composites of ceramic particles in a polymer matrix has been achieved by doping the polymer matrix material. Readily prepared and polarized films with various volume fractions of lead zirconate-titanate (PZT) particles in polyurethane have been doped in a solution of lithium perchlorate in acetone to increase the conductivity. With an appropriate conductivity, the dielectric permittivities of the ceramic particles and the polymer matrix become matched, resulting in an improvement of the pyroelectric coefficient from about 6 microC/(m(2)K) to about 50 microC/(m(2)K).

Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro).

Introduction: The exchange of Aalpha 16, Arg for Cys or His is the most common molecular defect in dysfibrinogenemia directly affecting the thrombin cleavage site involved in fibrinopeptide A (FPA) release. Other amino acid exchanges within the fibrinopeptide A have been only rarely reported.

Materials And Methods: In clinically asymptomatic dysfibrinogenemic patients with low functional plasma fibrinogen (Fg) levels and prolonged thrombin time but normal or slightly prolonged batroxobin (reptilase) time, mutation analysis was carried out by direct sequencing of the coding regions of the three fibrinogen genes.

The prothrombin nt20210 A allele as a risk factor for venous thromboembolism: detection of heterozygous and homozygous carriers by alternative methods.

The A allele of a G/A dimorphism at position nt20210 in the 3'-untranslated region of the prothrombin gene has been recently identified as a common risk factor for venous thrombosis. It is detected mostly by PCR amplification using a mutagenic primer and subsequent restriction analysis. We have applied two alternative methods--DGGE and SSCP-to analyse the nt20210 dimorphism in a series of 383 consecutive patients with deep venous thrombosis and in 144 controls.